Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Fortress Value Acquisition V Shares Quiet as SPAC Deals Continue
·

Fortress Value Acquisition V Shares Quiet as SPAC Deals Continue

Fortress Value Acquisition Corp. V traded near $10.10 Wednesday on low volume, with only 104 shares changing hands and no merger target announced. The SPAC’s market cap stood at about $364 million. Karen Park joined the board last week, receiving 30,000 founder shares. Comparable SPACs also hovered near their $10 offer prices amid a busy blank-check market.
June 3, 2026
Aether Stock Gets a Fresh SEC Jolt as $100 Million Shelf Goes Live
·

Aether Stock Gets a Fresh SEC Jolt as $100 Million Shelf Goes Live

Aether Holdings shares traded near $3.28 after the SEC declared its $100 million S-3 shelf registration effective late June 2. The company reported a wider quarterly loss, lower cash of $807,957, and a going-concern warning. Aether also raised $3.24 million in debt in May. Market value stood at $39.8 million with thin trading volume.
June 3, 2026
SpaceX Hits 10,000 Active Starlink Satellites as Falcon 9 Readies New Florida Launch
·

SpaceX sets $75 billion price for Nasdaq IPO, Musk moves forward with rare listing

SpaceX will price its IPO at $135 per share, aiming to raise $75 billion and value the company near $1.75 trillion, sources told Reuters. The company plans to list on Nasdaq as soon as June 12 under the ticker SPCX, selling 555.6 million new shares. Starlink generated over two-thirds of revenue and $1.2 billion in profit last quarter, while other units posted losses. Elon Musk holds 85% of voting power.
June 3, 2026
TaskUs Stock Drops Sharply as AI Outsourcing Play Gets Tested Again
·

TaskUs Stock Drops Sharply as AI Outsourcing Play Gets Tested Again

TaskUs shares fell 6.3% to $6.06 on the Nasdaq Wednesday, near session lows, as investors reacted to slowing growth and margin pressure despite rising AI services revenue. First-quarter service revenue rose 10.3% to $306.3 million, while adjusted EBITDA margin narrowed to 19.1%. The company reaffirmed its 2026 outlook but guided for slower Q2 growth. Broader tech and outsourcing stocks also declined.
June 3, 2026
Frontdoor Shares Slip After Q1 Beat
·

Frontdoor Shares Slip After Q1 Beat

Frontdoor Inc shares slipped nearly 1% to $61.31 early Wednesday on Nasdaq, trading without a fresh catalyst. The company last reported first-quarter revenue up 6% to $451 million and net income up 11% to $41 million. Market cap stood near $4.43 billion. Contract claims costs rose $6 million in Q1, partly due to inflation and bad weather.
June 3, 2026
Uni-Fuels Stock Drops Premarket as Shareholders Face a Big Vote Next Week
·

Uni-Fuels Stock Drops Premarket as Shareholders Face a Big Vote Next Week

Uni-Fuels Holdings shares dropped 12% to $0.66 in U.S. premarket trading Wednesday ahead of a June 8 shareholder vote on major changes to its capital structure. The company posted a first-quarter net loss of $376,087 despite revenue rising 64% to $83.2 million. The stock has swung between $0.60 and $11.00 over the past year. Brent crude rose 2.1% to $98.02 a barrel amid renewed Middle East tensions.
June 3, 2026
Mineralys Stock Drops Before Open After $150 Million Sale Tests Blood-Pressure Drug Bet
·

Mineralys Stock Drops Before Open After $150 Million Sale Tests Blood-Pressure Drug Bet

Mineralys Therapeutics shares dropped 8.7% premarket after the company priced a $150 million stock offering at $26.50 a share to fund a $200 million royalty buyout with Tanabe Pharma. The company also secured a five-year, $500 million term loan from Pharmakon Advisors. Lorundrostat, its lead hypertension drug, is under FDA review with a decision expected by December 2026. AstraZeneca’s rival drug Baxfendy was approved in May.
June 3, 2026
·

Verrica Shares Drop With Jefferies Conference Ahead, Cash Warning Still in Focus

Verrica Pharmaceuticals closed Tuesday at $5.80, down 2.2%, and last traded at $5.79 ahead of a June 4 investor presentation. The company reported $5 million in first-quarter revenue and a $9.7 million net loss, with $20.6 million in cash as of March 31. Analyst Raghuram Selvaraju rated the stock Buy with a $12 target. No new filings or product updates have been released in the past 48 hours.
June 3, 2026
Middlesex Water Stock Climbs Before the Open — The Quiet Utility Move Investors Are Watching
·

Middlesex Water Stock Climbs Before the Open — The Quiet Utility Move Investors Are Watching

Middlesex Water Co. shares traded at $52.71 premarket Wednesday, holding a 1.8% gain from the prior session without new company news. The move tracked broader strength in water utilities, with sector peers also rising. Middlesex last reported first-quarter net income of $10.6 million on $48.7 million revenue. The company invested $21 million in infrastructure in the quarter.
June 3, 2026
WeRide Buyback and Madrid Robotaxi Deal Put Traders on Watch
····

WeRide Buyback and Madrid Robotaxi Deal Put Traders on Watch

WeRide’s Nasdaq ADSs closed at $7.75 Tuesday, down 0.8%. The company said it will launch Spain’s first commercial robotaxi pilot with Uber in Madrid later this year, using AVOMO to operate the fleet. WeRide repurchased 201,500 Class A shares in Hong Kong on June 2 for HK$4.27 million. CLSA maintained its $11 U.S. price target and rated the Hong Kong stock Outperform.
June 3, 2026
Hemab Therapeutics Pulls Back After 53% IPO Surge
·

Hemab Therapeutics Pulls Back After 53% IPO Surge

Hemab Therapeutics (COAG) will open Wednesday pre-market at $27.47, up 53% from its $18 IPO price. The company raised $346.7 million in its May IPO, ending March with $163.5 million in cash before IPO proceeds. Hemab plans a pivotal Phase 3 trial for its lead drug, sutacimig, in Glanzmann thrombasthenia in late 2026. CEO Benny Sørensen said data from key programs is expected by late 2026 or early 2027.
June 3, 2026
EOSE Stock Climbs Before Crucial Share Vote as Eos Energy Bulls Eye Grid-Storage Funding
····

EOSE Stock Climbs Before Crucial Share Vote as Eos Energy Bulls Eye Grid-Storage Funding

Eos Energy Enterprises shares closed up 4.8% at $9.42 Tuesday, ahead of its annual meeting where investors will vote on raising authorized common stock to 800 million shares from 600 million. The company said only 7% of authorized shares remain available. Alessandro Lagi is set to become CFO on June 8. Trading volume reached about 26.4 million shares.
June 3, 2026
Aura Biosciences Stock Falls After Eye-Cancer Trial News
····

Aura Biosciences Stock Falls After Eye-Cancer Trial News

Aura Biosciences shares fell 4.2% to $6.89 Tuesday after the company announced it completed enrollment of 108 patients in its Phase 3 CoMpass trial for bel-sar in early choroidal melanoma. Topline results are expected in the second half of 2027. The company reported $114.7 million in cash at the end of March and raised $280.8 million more in a recent equity sale. Aura has no approved products and relies on bel-sar for future growth.
June 2, 2026
Funko Shares Fall as Attention Turns to $70 Million Turnaround Goal
····

Funko Shares Fall as Attention Turns to $70 Million Turnaround Goal

Funko Inc. shares fell 2.3% to $5.46 Tuesday, tracking declines in toy and entertainment stocks as broader markets slipped. No new company news drove the move. Funko posted Q1 net sales of $200.9 million and a net loss of $18.1 million, with Core Collectibles up but Loungefly sales down. The company held $34.3 million in cash and $215.9 million in debt as of March 31.
June 2, 2026
GIBO Stock Moves Before The Bell — The Tiny Volume Behind The AI Microcap’s Bounce
····

GIBO Stock Moves Before The Bell — The Tiny Volume Behind The AI Microcap’s Bounce

GIBO Holdings shares rose 3.1% to $1.34 in thin premarket trading Tuesday, recovering some of Monday’s losses. The company reported no revenue for 2025 and a $231.9 million net loss, with its auditor warning of “substantial doubt” about its ability to continue. GIBO had $402,736 in cash at year-end and agreed to a $5 million credit facility. The stock remains volatile, with a 52-week range of $1.16 to $538.
June 2, 2026
Masonglory Stock Gains, But $1 Nasdaq Listing Hurdle Still Ahead
····

Masonglory Stock Gains, But $1 Nasdaq Listing Hurdle Still Ahead

Masonglory shares jumped 14.77% to $0.5222 Monday but slipped to $0.5040 in pre-market trading Tuesday, still below Nasdaq’s $1 minimum. The Hong Kong subcontractor faces a September 2026 deadline to regain compliance after 30 straight days under $1 earlier this year. Recent filings showed six-month net income fell 80% to $146,780 on weaker revenue. No new company announcements explained Monday’s surge.
June 2, 2026
1 … 14 15 16 17 18 … 236